Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Gestational trophoblastic disease (GTD) is a rare group of interrelated tumors that develop after conception and lead to abnormal development of the placenta. More than 80 percent of GTD cases are non-cancerous. All forms of GTD can be treated, and in
the great majority of cases, cured. Most women who have had a single incidence of GTD can go on to have normal subsequent pregnancies.
There are three main types of GTD:
Hydatidiform mole, or molar pregnancy
A hydatidiform mole, also called a molar pregnancy, is a form of gestational trophoblastic disease that arises when fertilization of an egg results in an abnormal pregnancy. With a molar pregnancy, the fetus is never viable.
There are two types of molar pregnancies, complete and partial. A complete molar pregnancy develops when the fertilized egg lacks maternal genes. The pregnancy that results contains no fetal tissue and resembles grape-like cysts that fill the
uterine cavity. A partial molar pregnancy occurs when more than one sperm fertilizes a normal egg and results in a pregnancy in which both the fetus and placenta are abnormal. The term partial is used because the placenta contains both normal
tissue and grape-like cysts similar to that seen in complete moles.
Eighty percent of molar pregnancies are benign in that they cause no further trouble after they are removed from the uterus. However, in approximately 20 percent of complete molar pregnancies and 1-4 percent of partial moles, the molar tissue
either spreads locally within the muscular wall of the uterus (called invasive mole) or spreads more widely to other parts of the body, most commonly the lungs (called metastases), requiring treatment. Hydatidiform moles occur in only one
of every 1,000-1,200 pregnancies in the United States.
Choriocarcinoma is a highly malignant form of GTD that spreads rapidly throughout the body and requires vigorous treatment. It may have begun as a molar pregnancy or from tissue that remains in the uterus following a miscarriage or childbirth.
Choriocarcinoma is even less common, arising in only one of every 20,000-40,000 pregnancies.
Placental-site and epithelioid trophoblastic tumors
Placental-site and epithelioid trophoblastic tumors, are very rare forms of the disease that arises in the uterus at the site where the placenta was attached. These tumors penetrate the muscle layer of the uterus and usually do not spread to other
parts of the body.
Although doctors cannot always explain why a woman develops GTD, there are a number of factors that may increase a woman's risk of developing the disease:
The most common symptoms of hydatidiform mole are feeling pregnant and vaginal bleeding, which can be either bright red or watery brown discharge. Other symptoms include:
Women who develop choriocarcinoma may be symptom-free or experience symptoms based on which organ(s) is (are) involved:
Learn more about GTD from the International Society for the Study of Trophoblastic Diseases.
New Patient Appointments
We understand that a cancer diagnosis can be emotionally challenging, and that treatment can be physically demanding.
When you become a patient, our medical, nursing, and support teams make sure you
receive the best and most comprehensive care every step of the way.
As a Dana-Farber Brigham Cancer Center patient, you have access to an extensive array of support programs and services that address issues you may face before, during, and after your treatment.